12. Referenties
1.    Berden, F.A., et al., Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era. Neth J Med, 2014. 72(8): p. 388-400.
2.    Recommendations for Testing, Managing, and Treating Hepatitis C. www.hcvguidelines.org, 2016.
3.    European Association for the Study of the Liver. Electronic address, e.e.e., EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol, 2015.
4.    Christoph Sarrazin, T.B., Peter Buggisch, Matthias Dollinger, Holger Hinrichsen, Harald Hofer, Dietrich Hüppe, Michael Manns, Stefan Mauss, Jörg Petersen, Karl-Georg Simon, Ingo van Thiel, Heiner Wedemeyer, Stefan Zeuzem, Aktuelle Empfehlung zur Therapie der chronischen Hepatitis C. 2015.
5.    d'hépatologie, A.S.F., Recommandations AFEF sur la prise en charge des hépatites virales C. 2016.
6.    van der Meer, A.J., et al., Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA, 2012. 308(24): p. 2584-93.
7.    G.R. Foster, J.M., W. Irving, M. Cheung, B. Hudson, and K.A. S. Verma, and HCV Research UK EAP Group., Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks of sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV genotypes 1 and 3. J Hepatol, 2015. 62: p. S190.
8.    Tacke., F., et al., TREATMENT OF HCV GENOTYPE 2 WITH SOFOSBUVIR AND RIBAVIRIN RESULTS IN LOWSVR RATES IN A REALWORLD COHORT (GERMAN HEPATITIS C-REGISTRY, DHC-R). EASL abstract, 2016.
9.    Susser., S., et al., PREVALENCE AND CLINICAL IMPORTANCE OF HEPATITIS C VIRUS GENOTYPE 2 K/1B CHIMERAS. EASL abstract, 2016.
10.    Arends, J.E., et al., Treatment of acute hepatitis C virus infection in HIV+ patients: Dutch recommendations for management. Neth J Med, 2011. 69(1): p. 43-9.
11.    Lamers, M.H., et al., Treatment of hepatitis C monoinfection in adults--Dutch national guidelines. Neth J Med, 2013. 71(7): p. 377-85.
12.    Fierer, D.S., et al., Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis, 2014. 58(6): p. 873-9.
13.    Hullegie;, et al., SVR12 results after 12-weeks boceprevir, peginterferon and ribavirin in the Dutch Acute Hepatitis C in HIV study (DAHHS). J Hepatol, 2015. 62: p. S287.
14.    EMA. Summary of prodcut characteristics: Pegasys. 2007  [cited 2015 June 5]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000395/WC500039195.pdf.
15.    Barril, G., et al., Pegylated interferon-α2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers. Alimentary Pharmacology & Therapeutics, 2004. 20(1): p. 37-44.
16.    EMA, Summary of Product Characteristics: PegIntron. 2010.
17.    Gupta, S.K., et al., Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency. British Journal of Clinical Pharmacology, 2007. 64(6): p. 726-732.
18.    EMA, Copegus: prescibing information. 2011.
19.    Bruchfeld, A., et al., Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat, 2006. 13(5): p. 316-21.
20.    Fda. Copegus : Prescribing information. 2011; Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
21.    EMA. Olysio: Product Information. 2014  [cited 2015 February 15]; Available from: http://ec.europa.eu/health/documents/community-register/2014/20140514128513/anx_128513_en.pdf.
22.    Nazario., H.E., M. Ndungu., and A.A. Modi, Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/min. EASL abstract, 2016.
23.    Comellas, B., Treatmet of HCV withs imeprevir associated to daclatasvir in patients with stage 4 and 5 chornic renal failure. EASL abstract, 2016.
24.    Nazario, H.E., sofosbuvir-based, ribavirin-free regimens in patients with chronic hepatitis C and end-stage renal disease: a look at safety, tolerability and efficacy. EASL abstract, 2016.
25.    EMA, Summary of Product Characteristics: Solvaldi. 2014.
26.    Saxena, V., et al., Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: real-world experience from HCV-TARGET, in Annual Meeting of the European Association for the Study of the Liver (EASL). 2015: Vienna.
27.    Gane, E.J., et al., Safety, Antiviral Efficacy, and Pharmacokinetics of Sofosbuvir in Patients With Severe Renal Impairment in Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 2014: Boston.
28.    Nazario, H.E., M. Ndungu, and A. Modi, Safety and efficacy of sofosbuvir + simeprevir without ribavirin in hepatitis C genotype 1-infected patients with end-stage renal disease or GFR<30ml/min, in Annual Meeting of the European Association for the Study of the Liver (EASL). 2015: Vienna.
29.    Beinhardt, S., et al., Real life experience with interferon/ribavirin free antiviral treatment in renal transplant recipients and end stage renal disease patients on dialysis infected with hepatitis C virus, in Annual Meeting of the European Association for the Study of the Liver (EASL). 2015: Vienna.
30.    Desnoyer, A., et al., Sofosbuvir in haemodialysis: 400mg daily only the day of haemodialysis? , in 16th Workshop of Clinical pharmacology of HIV and Hepatitis Therapy. 2015: Washington, DC.
31.    Desnoyer, A., et al., Sofosbuvir-containing regimen for HCV infection in hemodialysis patients: 400 mg daily or only on the day of hemodialysis. EASL abstract, 2016.
32.    EMA. Daklinza: Summary of Product Characteristics. 2014; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003768/WC500172848.pdf.
33.    EMA. Summary of Product Characteristics: Viekirax. 2015  [cited 2015 June 5]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003839/WC500183997.pdf.
34.    Pockros, P.J., et al., Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-1 study, in Annual Meeting of the European Association for the Study of the Liver (EASL). 2015: Vienna.
35.    EMA. Summary of Product Characteristics: Exviera. 2015  [cited 2015 June 5]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003837/WC500182233.pdf.
36.    EMA. Harvoni: Product Information. 2014 November 17 [cited 2015 February 15]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003850/WC500177995.pdf.
37.    P.J. Pockros, K.R.R., P.S. Mantry, E. Cohen, M. Bennett,, D.B. M.S. Sulkowski, T. Podsadecki, D. Cohen,, and D.W. N.S. Shulman, A. Khatri, M. Abunimeh, E. Lawitz., Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV G1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-1 study. J Hepatol, 2015. 62: p. S 257.
38.    Nazario, H.E., M. Ndungu, and A.A. Modi, Sofosbuvir and Simeprevir in Hepatitis C genotype 1- patients with End-Stage Renal Disease on hemodialysis or GFR <30mL/min. Liver Int, 2015.
39.    Hundemer, G.L., et al., Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infect Dis (Lond), 2015. 47(12): p. 924-9.
40.    Burger, D.M., et al., Drug-drug interactions with direct acting antivirals against hepatitis C virus infection. Tijdschrift voor Infectieziekten, 2016. 11(2): p. 45-51.
41.    Terrault, N., et al., (HCV-TARGET) - Treatment Outcomes With 8, 12 and 24 Week Regimens of Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Infection: Analysis of a Multicenter Prospective, Observational Study Hepatology, 2015. 61(S1): p. 254A-258A.
42.    Back, D.J. and D.M. Burger, Interaction Between Amiodarone and Sofosbuvir-based Treatment for Hepatitis C Virus Infection: Potential Mechanisms and Lessons to be Learned. Gastroenterology, 2015. 149(6): p. 1315-7.
43.    Fontaine, H., et al., Bradyarrhythmias Associated with Sofosbuvir Treatment. N Engl J Med, 2015. 373(19): p. 1886-8.


index.html